Overview

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, single-center, open-label, umbrella-shaped phase II clinical study for patients with HR+/HER2- endocrine-resistant advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Capecitabine
Everolimus
Paclitaxel